109 related articles for article (PubMed ID: 15210146)
21. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
22. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
23. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.
Steuber H; Czodrowski P; Sotriffer CA; Klebe G
J Mol Biol; 2007 Nov; 373(5):1305-20. PubMed ID: 17905306
[TBL] [Abstract][Full Text] [Related]
24. High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Hazemann I; Dauvergne MT; Blakeley MP; Meilleur F; Haertlein M; Van Dorsselaer A; Mitschler A; Myles DA; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1413-7. PubMed ID: 16204895
[TBL] [Abstract][Full Text] [Related]
25. Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.
Rogniaux H; Van Dorsselaer A; Barth P; Biellmann JF; Barbanton J; van Zandt M; Chevrier B; Howard E; Mitschler A; Potier N; Urzhumtseva L; Moras D; Podjarny A
J Am Soc Mass Spectrom; 1999 Jul; 10(7):635-47. PubMed ID: 10384727
[TBL] [Abstract][Full Text] [Related]
26. Structure of rat aldose reductase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis.
Sundaram K; Dhagat U; Endo S; Chung R; Matsunaga T; Hara A; El-Kabbani O
Bioorg Med Chem Lett; 2011 Jan; 21(2):801-4. PubMed ID: 21168333
[TBL] [Abstract][Full Text] [Related]
27. Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
Iwata Y; Naito S; Itai A; Miyamoto S
Drug Des Discov; 2001; 17(4):349-59. PubMed ID: 11765138
[TBL] [Abstract][Full Text] [Related]
28. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
Ferrari AM; Degliesposti G; Sgobba M; Rastelli G
Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536
[TBL] [Abstract][Full Text] [Related]
29. Virtual screening for inhibitors of human aldose reductase.
Kraemer O; Hazemann I; Podjarny AD; Klebe G
Proteins; 2004 Jun; 55(4):814-23. PubMed ID: 15146480
[TBL] [Abstract][Full Text] [Related]
30. Aldose reductase as a target for drug design: molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme.
De Winter HL; von Itzstein M
Biochemistry; 1995 Jul; 34(26):8299-308. PubMed ID: 7599122
[TBL] [Abstract][Full Text] [Related]
31. A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway.
Rath J; Gowri VS; Chauhan SC; Padmanabhan PK; Srinivasan N; Madhubala R
Gene; 2009 Jan; 429(1-2):1-9. PubMed ID: 18983902
[TBL] [Abstract][Full Text] [Related]
32. 3D-pharmacophore analyses of aldose reductase inhibitory spiroquinazolinones.
Nakao K; Asao M; Shirai H; Shimizu R
Drug Des Discov; 1999 Aug; 16(2):155-63. PubMed ID: 10533811
[TBL] [Abstract][Full Text] [Related]
33. Electrostatic fields near the active site of human aldose reductase: 1. New inhibitors and vibrational stark effect measurements.
Webb LJ; Boxer SG
Biochemistry; 2008 Feb; 47(6):1588-98. PubMed ID: 18205401
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
Dhagat U; Endo S; Hara A; El-Kabbani O
Bioorg Med Chem; 2008 Mar; 16(6):3245-54. PubMed ID: 18165015
[TBL] [Abstract][Full Text] [Related]
35. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.
Kurono M; Fujii A; Murata M; Fujitani B; Negoro T
Biochem Pharmacol; 2006 Jan; 71(3):338-53. PubMed ID: 16324683
[TBL] [Abstract][Full Text] [Related]
36. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat.
Rastelli G; Costantino L
Bioorg Med Chem Lett; 1998 Mar; 8(6):641-6. PubMed ID: 9871575
[TBL] [Abstract][Full Text] [Related]
38. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Cosconati S; Marinelli L; La Motta C; Sartini S; Da Settimo F; Olson AJ; Novellino E
J Med Chem; 2009 Sep; 52(18):5578-81. PubMed ID: 19719141
[TBL] [Abstract][Full Text] [Related]
39. An integrative approach combining noncovalent mass spectrometry, enzyme kinetics and X-ray crystallography to decipher Tgt protein-protein and protein-RNA interaction.
Ritschel T; Atmanene C; Reuter K; Van Dorsselaer A; Sanglier-Cianferani S; Klebe G
J Mol Biol; 2009 Nov; 393(4):833-47. PubMed ID: 19627989
[TBL] [Abstract][Full Text] [Related]
40. Exploring structural requirements for aldose-reductase inhibition by 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues: Fujita-Ban and Hansch approach.
Soni LK; Kaskhedikar SG
Arch Pharm (Weinheim); 2006 Jun; 339(6):327-31. PubMed ID: 16622827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
